Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation

被引：21

作者：

Kim R. ^{[1
]}

Aucejo F. ^{[1
]}

机构：

[1] Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, R35

来源：

Journal of Gastrointestinal Cancer | 2011年 / 42卷 / 1期

关键词：

Sirolimus and hepatocellular carcinoma; Sorafenib;

D O I：

10.1007/s12029-010-9196-2

中图分类号：

学科分类号：

摘要：

Background: No standard therapies have been established for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation. Discussion: Sirolimus is a mTOR inhibitor which has been used as an immunosuppressive medication in patients who are at high risk of tumor reoccurrence after liver transplantation. Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC. However the role of sorafenib in patients with HCC reoccurrence after liver transplantation is unclear. Results: Combination of sirolimus and sorafenib appears to have synergistic effect when treating HCC in preclinical settings. We report a case of a post-liver transplant patient treated with sorafenib and sirolimus for hepatic HCC recurrence who exhibited complete radiologic response after 5Â months of therapy. © 2010 Springer Science+Business Media, LLC.

引用

页码：50 / 53

页数：3

共 11 条

[1]

Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, New England Journal of Medicine, 334, 11, pp. 693-699, (1996)

[2]

Kirimlioglu H., Dvorchick I., Ruppert K., Finkelstein S., Marsh J.W., Iwatsuki S., Bonham A., Carr B., Nalesnik M., Michalopoulos G., Starzl T., Fung J., Demetris A., Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: Biologic and therapeutic implications, Hepatology, 34, 3, pp. 502-510, (2001)

[3]

Zhou J., Wang Z., Wu Z.Q., Qiu S.J., Yu Y., Huang X.W., Tang Z.Y., Et al., Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria, Transplant Proc, 40, pp. 3548-3553, (2008)

[4]

Zimmerman M.A., Trotter J.F., Wachs M., Bak T., Campsen J., Skibba A., Kam I., Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma, Liver Transplantation, 14, 5, pp. 633-638, (2008)

[5]

Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., Tovar V., Et al., Pivotal role of mTOR signaling in hepatocellular carcinoma, Gastroenterology, 135, pp. 1972-1983, (2008)

[6]

Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Et al., Efficacy and safety of sorafenib in patients in the Asia Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, pp. 25-34, (2009)

[7]

Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., De Oliveira A.C., Et al., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, pp. 378-390, (2008)

[8]

Newell P., Toffanin S., Villanueva A., Chiang D.Y., Minguez B., Cabellos L., Savic R., Et al., Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo, J Hepatol, 51, pp. 725-733, (2009)

[9]

Wang Z., Zhou J., Fan J., Qiu S.J., Yu Y., Huang X.W., Tang Z.Y., Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma, Clin Cancer Res, 14, pp. 5124-5130, (2008)

[10]

Hainsworth J.D., Spigel D.R., Burris III H.A., Waterhouse D., Clark B.L., Whorf R., Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma, J Clin Oncol, 28, pp. 2131-2136, (2010)

← 1 2 →